Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
growth tags : Trial save search
Global $4.1 Billion Clinical Trial Supplies Market Report 2024-2034 - Emerging Markets Catalyzing Growth in Clinical Trial Supplies
Published: 2024-03-26 (Crawled : 17:00) - prnewswire.com
JNJ | News | $148.53 -0.69% 0.11% 67K
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: 0.0%
ICLR | News | $309.44 0.98% 0.76% 8
|
Health Technology
|
| O: 0.46%
H: 0.65%
C: -0.43%
report global trial growth market
TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency
Published: 2023-12-19 (Crawled : 13:30) - globenewswire.com
ASND | $143.18 -1.14% -1.18% 0
|
Health Technology
|
| O: 0.99%
H: 1.39%
C: 0.93%
trial growth hormone
Clinical Trial Services Market to Exhibit Significant Growth at 6.11% CAGR, Garnering $72.54 Billion by 2030, with North America Leading the Industry as Demand for Innovative Therapies Rises, States Kings Research
Published: 2023-12-15 (Crawled : 15:00) - prnewswire.com
LH 4 | $207.94 -0.01% 0.03% 0
|
Health Services
|
| O: -0.77%
H: 0.63%
C: -0.84%
CRL | News | $239.43 -0.29% 0.0% 1
|
Commercial Services
|
| O: 0.02%
H: 0.73%
C: 0.66%
MEDP | $397.56 -2.36% -2.35% 15
|
Commercial Services
|
| O: 0.24%
H: 1.67%
C: 0.27%
ICLR | News | $309.44 0.98% 0.76% 8
|
Health Technology
|
| O: 0.6%
H: 0.54%
C: -0.23%
america services research trial growth market
Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency
Published: 2023-11-21 (Crawled : 21:00) - globenewswire.com
LUMO | $2.795 -0.18% -0.18% 0
|
Health Technology
|
| O: -1.64%
H: 4.66%
C: 2.67%
lum-201 pharma treatment trial potential growth hormone
Clinical Trial Supplies Market to grow by USD 1.19 billion from 2022 to 2027 | The growth of the biopharmaceutical industry drives the market growth - Technavio
Published: 2023-11-13 (Crawled : 03:00) - prnewswire.com
TMO | News | $577.39 0.49% -0.38% 1.7M
|
Health Technology
|
| O: 0.58%
H: 0.0%
C: 0.0%
trial growth market
Ascendis Pharma Presents Results from Long-Term enliGHten Trial of TransCon™ hGH in Pediatric Growth Hormone Deficiency
Published: 2023-09-23 (Crawled : 12:20) - globenewswire.com
ASND | $143.18 -1.14% -1.18% 0
|
Health Technology
| Email alert
Add to watchlist
pharma trial results growth hormone
CGC MONDAY DEADLINE: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Canopy Growth Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important July 24 Deadline in Securities Class Action - CGC
Published: 2023-07-22 (Crawled : 20:20) - prnewswire.com
CGC | $8.96 14.14% 12.39% 7.4M
|
Process Industries
| Email alert
Add to watchlist
AER | News | $85.11 -1.18% 0.81% 10
|
Finance
| Email alert
Add to watchlist
corporation deadline trial growth
FULC INVESTOR NOTICE: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Fulcrum Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - FULC
Published: 2023-06-03 (Crawled : 04:20) - prnewswire.com
CGC | $8.96 14.14% 12.39% 7.4M
|
Process Industries
| Email alert
Add to watchlist
FULC | $7.28 -2.15% -2.27% 0
|
Health Technology
| Email alert
Add to watchlist
HSAI | $4.28 0.94% 0.82% 50
|
n/a
| Email alert
Add to watchlist
trusted deadline trial
HSAI FINAL DEADLINE ALERT: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Hesai Group Investors to Secure Counsel Before Important June 6 Deadline in Securities Class Action Filed by the Firm - HSAI
Published: 2023-06-03 (Crawled : 00:20) - prnewswire.com
RLMD | $3.86 -1.28% -1.56% 730
|
Health Technology
| Email alert
Add to watchlist
CGC | $8.96 14.14% 12.39% 7.4M
|
Process Industries
| Email alert
Add to watchlist
HSAI | $4.28 0.94% 0.82% 50
|
n/a
| Email alert
Add to watchlist
deadline group trial
QSAM Biosciences to Provide Updates on its Clinical Trial at the Emerging Growth Conference on Wednesday, March 22, 2023
Published: 2023-03-20 (Crawled : 14:00) - biospace.com/
QSAM | $8.25 1.35% -31.58% 0
|
Manufacturing
|
| O: -4.48%
H: 7.41%
C: 7.41%
conference trial growth
Clinical trial management system (CTMS) market size to increase by USD 1,449.16 million between 2022 and 2027; Growth driven by increasing healthcare expenditure - Technavio
Published: 2023-03-11 (Crawled : 08:20) - prnewswire.com
VEEV | $200.52 -0.29% -0.38% 550K
|
Technology Services
| Email alert
Add to watchlist
management system trial growth market
Hoth Therapeutics Announces Collaboration with First Active Clinical Site for its Phase 2 Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy
Published: 2023-03-08 (Crawled : 17:00) - biospace.com/
HOTH | $1.17 -1.68% 1.2% 0
|
Health Technology
|
| O: -0.37%
H: 4.49%
C: 2.62%
active collaboration trial therapeutics therapy cancer growth
Hoth Therapeutics Announces Selection of First 3 Clinical Sites for its Phase 2 Clinical Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy
Published: 2023-01-25 (Crawled : 15:20) - biospace.com/
HOTH | $1.17 -1.68% 1.2% 0
|
Health Technology
|
| O: -1.76%
H: 2.79%
C: 2.79%
trial therapeutics therapy cancer growth
Meirowitz & Wasserberg Continues Growth, Adds Experienced Trial Attorney Danny Kraft
Published: 2022-08-08 (Crawled : 13:00) - prnewswire.com
JNJ | News | $148.53 -0.69% 0.11% 67K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
CR | $142.13 2.91% 3.22% 250
|
Producer Manufacturing
|
| O: 0.51%
H: 0.35%
C: -0.37%
trial
Genexine Announces Completion of Enrollment in Phase 3 Clinical Trial with Its Proprietary Long-acting Growth Hormone, GX-H9/TJ101 (Eftansomatropin alfa)
Published: 2022-06-14 (Crawled : 10:00) - biospace.com/
IMAB | $1.81 0.56% 0.28% 0
|
Health Technology
|
| O: -3.71%
H: 0.0%
C: 0.0%
tj101 trial growth phase 3
I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin alfa for Treatment of Pediatric Growth Hormone Deficiency
Published: 2022-05-31 (Crawled : 21:00) - biospace.com/
IMAB | $1.81 0.56% 0.28% 0
|
Health Technology
|
| O: 4.47%
H: 9.37%
C: 0.69%
treatment trial growth hormone
VISEN Pharmaceuticals Announces Top-line Results of Phase 3 Trial of Once-Weekly Lonapegsomatropin, Demonstrating Superior Efficacy, Comparable Safety and Tolerability to Daily Growth Hormone
Published: 2022-05-23 (Crawled : 08:00) - prnewswire.com
ASND | $143.18 -1.14% -1.18% 0
|
Health Technology
|
| O: 4.07%
H: 2.7%
C: 1.55%
trial results growth hormone phase 3 topline
Rejuvenate Biomed Started a Groundbreaking Clinical Trial and Expands for Future Growth
Published: 2022-03-29 (Crawled : 07:00) - prnewswire.com
JNJ | News | $148.53 -0.69% 0.11% 67K
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
trial growth
New Analysis from Global Industry Analysts Reveals Steady Growth for Industrial Gearbox, with the Market to Reach $49.2 Billion Worldwide by 2026
Published: 2022-03-21 (Crawled : 15:00) - prnewswire.com
EMR | $109.62 -0.14% 0.0% 1.6M
|
Producer Manufacturing
|
| O: 0.87%
H: 1.1%
C: 0.37%
als trial growth
USD 175.3 million growth expected in Generative Design Market | Availability of trial or free versions to drive growth | Technavio
Published: 2022-03-21 (Crawled : 12:30) - prnewswire.com
ALTR | $83.45 -0.39% -0.35% 0
|
Technology Services
|
| O: -0.76%
H: 1.23%
C: -1.18%
trial growth designation
Gainers vs Losers
| 59% | 41% |
Top 10 Gainers
BOF | $2.08 77.78% 39.06% 110M
|
OPTN | $0.9253 -4.38% 30.38% 5.3M
|
Health Services
SGBX | $0.1441 -2.24% 29.47% 6.1M
|
Producer Manufacturing
PCSA | $1.62 1.25% 21.95% 7.1M
|
Producer Manufacturing
BHIL | $0.1793 -4.37% 19.24% 340K
|
Agriculture, Forestry, Fishing ...
UMAC | $1.48 -1.33% 14.87% 20K
|
CI | $352.28 -0.11% 13.53% 2
|
Health Services
SPCB | News 4 d | $0.2236 -6.83% 12.09% 20M
|
Electronic Technology
BMTX 4 | $1.545 0.98% 10.03% 2.5K
|
Information
OMQS | $0.411 -2.81% 9.83% 1.2M
|
Professional, Scientific, and T...
Your saved searches
Save your searches and get alerts when important news are released.